Table 1.
Summary of included studies and their characteristics.
| Study | Type | Patient no. | Aim/intervention | % Relapsed | % MAT |
|---|---|---|---|---|---|
| Ashraf 2013 [16] | Retrospective database review in single centre | 27 | Describe response, survival and toxicity of cyclophosphamide and topotecan in children with 1st relapse of NB | 96 | 93 |
| Bagatell 2011 [17] | Prospective single arm cohort in COG centres | 27a | Determine response rate of irinotecan and temozolomide in relapsed/refractory NB | 77 | NR |
| Di Giannatale 2014 [18] | Prospective single arm cohort in Europe | 38 | Assess objective response rate of 2 cycles of topotecan & temozolomide chemo | 66 | 61 |
| Garaventa 2003 [19] | Prospective single arm cohort in Italy | 25 | Evaluate anti-tumour activity and tolerability of topotecan/vincristine/doxorubicin) in children with advanced NB | 24 | 52 |
| Kushner 2010 [20] | Retrospective database review in single centre | 30a | Assess likelihood of response to high dose cyclophosphamide/topotecan/vincristine | 100 | 70 |
| Rubie 2006 [21] | Prospective single arm cohort in Europe | 25 | Determine response rate of NB to temozolomide | 60 | 64 |
| Simon 2007 [22] | Prospective single arm cohort in Germany | 40 | Trial of topotecan & etoposide in the treatment of patients with relapsed HRNB | 100 | 30 |
| Simon 2007 [23] | Prospective single arm cohort in Germany | 33a | Trial of topotecan/cyclophosphamide/etoposide in the treatment of patients with HRNB | 100 | 52 |
| Mody 2017 [24] | Randomised Control Trial in COG centres | 35 | Comparison of temozolomide & irinotecan chemotherapy with additional temsirolimus or dinutuximab in 1st relapse of HRNB | 56 & 53 | 50 & 59 |
MAT, myeloablative therapy with autologous stem cell rescue; NR, not reported; NB, neuroblastoma; HRNB; high-risk neuroblastoma; COG, Children's oncology group.
a
n = number of participants from the entire cohort in eligible sub group(s).